Nandrolone Phenylpropionate (NPP) is an injectable anabolic/androgenic steroid. It is highly anabolic and mildly androgenic. NPP is very similar to the very popular steroid Deca which is nandrolone but with a longer ester (decanoate). Nandrolone Phenylpropionate is, therefore, a shorter acting Deca for all practical intents and purposes
Anecdotally, it seems to produce less water retention than its longer acting cousin so consistent with injectable testosterones, where we find that shorter esters provide much less water retention. NPP has also been proven to have more side effects than Nandrolone Decanoate especially in regards to reducing the presence of ‘Deca Dick’ and offers a cleaner, sharper look to the muscles than its longer acting cousin
Due to the chemical structure of NPP this product is susceptible to crashing if exposed to temperatures below 6° Celcius (48.8F) for any length of time. Storage MUST be maintained between 6C and 30C as stated on the vial label and customers in cold climates must be advised that this product could reach you in a ‘crashed’ state. If it does then please read our ‘How to Recover Re-crystallized Gear’ in the forums.
View IA Superpharma USA-Lite all product range by visiting the Shop Page.
|EACH ML CONTAINS:|
|Grape Seed Oil||BP||q.s.|
Dosage and administration:
Half life between 3 days
Adult dose (male): 200-600mg EOD or ETD by intramuscular injection
Adult dose (female): 25-50mg EOD or ETD by intramuscular injection
Average Cycle Length: 4-12weeks following an EOD, ETD injection pattern
Anabolic #: 37
Androgenic #: 125
Bioavailability: Estimated at 100%
CAS Name: 17-Hydroxyestra-4-en-3-one
Contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate and in women who are or may become pregnant. When administered to pregnant women, androgens cause virilization of the external genitalia of the female fetus. This virilization includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure. Geriatric patients treated with androgens may be at an increased risk for the development of prostatic hypertrophy and prostatic carcinoma.